(54.173.229.84)
Users online: 10995     
Ijournet
Email id
 

Indian Journal of Public Health Research & Development
Year : 2019, Volume : 10, Issue : 9
First page : ( 664) Last page : ( 669)
Print ISSN : 0976-0245. Online ISSN : 0976-5506.
Article DOI : 10.5958/0976-5506.2019.02509.9

Effect of Thyroid Hormone Abnormalities on Hemoglobin A1c in Hemodialysis Patients Taking Erythropoietin

Al-Omary Hanan L.1, Alawad Zainab M.2,*, Husseini Buraq3

1PhD, Assistant Professor, Physiology Department, College of Medicine, University of Baghdad

2MSc, Assistant Lecturer, Physiology Department, College of Medicine, University of Baghdad

3MSc, Assistant Lecturer, Doctor, Department of Anesthesia Techniques, Al-Nisour University College

*Corresponding Author: Zainab M. Alawad, MSc, Assistant Lecturer, Physiology Department, College of Medicine, University of Baghdad Bab Al Muadam P.O. Box 61023, Mail Code 12114, Baghdad-Iraq Email: zainabm.alawad@gmail.com

Online published on 13 November, 2019.

Abstract

Background

Hemoglobin A1c (HbA1c) is a widely used test for glycemic control. It is done for chronic kidney disease (CKD) patients. Renal disease is accompanied by thyroid abnormalities, which affect HbA1c, especially in those taking erythropoiesis-stimulating agents (ESAs). We aimed to find the effect of thyroid dysfunction on HbA1c in hemodialysis patients taking ESAs and those who do not.

Materials and Method

Fifty six patients were included in this study, which was done between September 2017 and June 2018, in Baghdad Teaching Hospital. Thyroid stimulating hormone, free T3, free T4 and HbA1c measurements were done. The patients were divided into 2 groups; those who took ESAs and those who did not, then they were subdivided into those with hypothyroidism and hyperthyroidism according to the Body mass index (BMI).

Results

Comparing HbA1c levels in hemodialysis patients taking ESAs and those who did not, showed no significant difference (5.79 ± 1.91 vs. 6.19 ± 1.64, P=0.09). The difference was also not significant in both hypothyroid and hyperthyroid patients in both high and low BMI patients. The only significant difference in HbA1c was between hyperthyroid and hypothyroid patients in those not taking ESAs, and having low BMI (4.97 ± 1.36 and 7.51 ± 0.87 respectively, P=0.02).

Conclusion

There is no significant influence of thyroid hormone changes on HbA1c levels in hemodialysis patients taking and not taking ESAs.

Top

Keywords

Hemoglobin A1c, Chronic kidney disease, Thyroid dysfunction, Hemodialysis, Erythropoiesisstimulating agents.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
733,042,471 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.